Acute renal failure with the combined use of rosuvastatin and fenofibrate.
Among the lipid-lowering drugs, the statins and fibrates are the most commonly used agents. Either class of drug is considered relatively safe. Though a variety of albeit uncommon adverse side effects have been observed with both classes, most of these therapeutic complications can be managed without discontinuation of the offending drug. Sometimes, especially in patients with extremely high cholesterol and/or triglyceride levels, a combination regimen is deemed necessary. However, the combined use of lipid-lowering drugs increases the incidence and severity of adverse events. In this article, we report an unusual case of acute renal failure (ARF) in a patient who had been prescribed both a statin (rosuvastatin) and a fibrate (fenofibrate).
Buyukhatipoglu
Hakan
H
Department of Internal Medicine, Harran University School of Medicine, Sanliurfa, Turkey. buyukhatipoglu@gmail.com
Sezen
Yusuf
Y
Guntekin
Unal
U
Kirhan
Idris
I
Dag
Omer Faruk
OF
D058186:Acute Kidney Injury / Q000139:chemically induced*; D000328:Adult; D004347:Drug Interactions; D005260:Female; D011345:Fenofibrate / Q000009:adverse effects*; D005464:Fluorobenzenes / Q000009:adverse effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000009:adverse effects*
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D011345:Fenofibrate